|
C-cell hyperplasia of thyroid
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The noncarriers included seven persons who had previously undergone thyroidectomies for suspected C-cell hyperplasia but were negative for the RET mutation present in affected members of their families.
|
7985085 |
1994 |
|
C-cell hyperplasia of thyroid
|
0.200 |
Biomarker
|
disease |
BEFREE |
C-cell hyperplasia due to some mechanism other than the presence of the MEN2A gene may also occur in MEN2A kindreds.
|
8094268 |
1993 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Histologic examination of the thyroid glands in the two RET mutation negative individuals who had thyroidectomy demonstrated C-cell hyperplasia in one but not in the other.
|
8849577 |
1996 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recently, a somatic mutation at codon 918 of RET was reported in medullary thyroid carcinoma (MTC) and C-cell hyperplasia in patients with MEN 2A or familial MTC (FMTC), suggesting its possible contribution to tumorigenesis.
|
9263528 |
1997 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Among RET mutation-positive patients, thyroidectomy performed for clinical or biochemical indication disclosed medullary thyroid carcinoma in 44 (98%) of 45 patients and precursor C-cell hyperplasia in only 1 (2%) patient.
|
9301617 |
1997 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
C-cell hyperplasia (CCH) and medullary thyroid carcinoma (MTC) in patients affected by germline mutations of the RET oncogene represent an exceptional opportunity to study the regulation of proliferation and apoptosis during tumour initiation and progression.
|
11037345 |
2000 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Genetic testing for RET germline mutations affords rapid identification of germline carriers, offering the prospect of cure before C-cell hyperplasia (CCH) has progressed to medullary thyroid carcinoma (MTC).
|
11376404 |
2001 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Gene carriers with noncysteine RET mutations had a lower incidence of medullary thyroid carcinoma (78.2% vs. 94.1%) than those with mutation in exon 10; 20.2% had C cell hyperplasia only, although thyroidectomized at an older age.
|
11502806 |
2001 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Sequencing analysis of the RET proto-oncogene revealed a Cys634Trp (TGC->TGG) mutation in all clinically affected family members and in an asymptomatic 5-year-old child who, after thyroidectomy, was found to have multicentric medullary thyroid carcinoma and C-cell hyperplasia.
|
11939755 |
2002 |
|
C-cell hyperplasia of thyroid
|
0.200 |
Biomarker
|
disease |
BEFREE |
In order to study the relationship between a misfunctioning of the RET proto-oncogene and the presence of C-cell hyperplasia, we compared a series of thyroid glands presenting sporadic or radiation-associated tumours, as well as samples of unrelated normal thyroid tissues, for alteration in exons 10 and 11 of the gene and for the presence or absence of C-cell hyperplasia.
|
12085189 |
2002 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The presence of C cell hyperplasia should always be reported; however its usefulness for indicating familial risk is limited and its role as a preneoplastic condition in patients without RET-protooncogene mutations remains to be elucidated.
|
12089863 |
2002 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In most examined populations the RET germline polymorphism S836S is found in about 3.6% of the normal population but in about 9% of patients suffering from sporadic C-cell hyperplasia or medullary thyroid carcinoma.
|
12410354 |
2002 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Although RET mutation is likely sufficient to cause C-cell hyperplasia, the precursor lesion to MTC, tumor progression is thought to be due to clonal expansion caused by the accumulation of somatic events.
|
12679485 |
2003 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The study objective was to investigate the impact of RET genotype on disease progression from C-cell hyperplasia (CCH) to MTC.
|
14555929 |
2003 |
|
C-cell hyperplasia of thyroid
|
0.200 |
Biomarker
|
disease |
BEFREE |
We conclude that we have identified a new syndrome, characterized by familial non-RET C cell hyperplasia.
|
14557476 |
2003 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
There was a significant age-related progression from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, nodal metastasis in patients whose RET mutations were grouped according to the extracellular- and intracellular-domain codons affected and in those with the codon 634 genotype.
|
14561794 |
2003 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
It is likely that the mutation causes familial medullary thyroid carcinoma (FMTC), because no other mutation was found in RET, the mutation cosegregates with medullary thyroid carcinoma (MTC) or C cell hyperplasia (CCH) in patients subjected to surgery, and family members without the mutation are clinically unaffected.
|
14602786 |
2003 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Individual germline mutations in the RET (REarranged during Transfection) proto-oncogene may set the time window for malignant progression from C-cell hyperplasia to familial medullary thyroid carcinoma.
|
15523405 |
2004 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Seventeen cases of MTC or bilateral C-cell hyperplasia (CCH) and separate occult PTC were identified from 16 different families.
|
15588381 |
2004 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We analyzed 6 MTCs and 1 C-cell hyperplasia (CCH) specimen from 7 patients with MEN2A and RET germline mutations in codons 609, 618, 620, or 634, using microdissection, microsatellite analysis, phosphorimage densitometry, and VHL mutation analysis.
|
16707008 |
2006 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia.
|
17384213 |
2007 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
|
18976163 |
2008 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In this study, we analyze whether stroma reaction seen by Tn-C expression is detected early in tumorigenesis of medullary thyroid carcinoma (MTC) including medullary microcarcinoma and C-cell hyperplasia (CCH), which is accepted to be a precursor lesion of MTC in the setting of RET oncogene germ-line mutation.
|
19484261 |
2009 |
|
C-cell hyperplasia of thyroid
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Germline RET proto-oncogene mutations are the genetic causes of multiple endocrine neoplasia type 2 and a strong genotype-phenotype correlation exists, particularly between a specific RET codon mutation and the (a) age-related onset and (b) thyroid tumor progression, from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, to nodal metastases.
|
22584703 |
2012 |